{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-105199","form_type":"8-K","ticker":"LQDA","cik":"0001819576","company_name":"Liquidia Corp","filed_at":"2025-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.594662+00:00","generated_at":"2026-05-17T00:56:05.386297+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Liquidia Q3 2025: first YUTREPIA sales of $51.7M, achieves profitability, net loss narrows to $3.5M","bullets":["Net product sales of YUTREPIA $51.7M in first full quarter post-launch; operating income of $1.7M, positive adjusted EBITDA $10.1M.","Net loss narrowed to $3.5M ($0.04 loss per share) from $31.0M ($0.40 loss per share) in Q3 2024.","More than 2,000 unique patient prescriptions and 1,500 patient starts to date, supported by 600+ prescribers.","Cash and equivalents $157.5M at Sept 30, 2025; R&D down 21% to $9.3M; SG&A up 98% to $40.1M reflecting commercialization."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-105199","json":"https://secwatch.observer/filing/0001104659-25-105199.json","markdown":"https://secwatch.observer/filing/0001104659-25-105199.md","text":"https://secwatch.observer/filing/0001104659-25-105199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819576/000110465925105199/0001104659-25-105199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819576/000110465925105199/tm2530004d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:56:05.386297+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}